Health Care & Life Sciences » Biotechnology | NewLink Genetics Corp.

NewLink Genetics Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
61,540.00
202,797.00
197,800.00
131,490.00
158,708.00
120,738
Total Accounts Receivable
1,657.00
19,333.00
5,388.00
30,501.00
10,532.00
798
Other Current Assets
773.00
8,333.00
4,954.00
5,921.00
6,226.00
5,536
Total Current Assets
63,970.00
230,463.00
208,142.00
167,912.00
175,466.00
127,072
Net Property, Plant & Equipment
6,587.00
7,599.00
10,400.00
6,835.00
5,091.00
3,727
Long-Term Note Receivable
-
-
-
-
140.00
-
Total Assets
70,557.00
238,062.00
218,542.00
174,747.00
180,697.00
130,939
ST Debt & Current Portion LT Debt
189.00
192.00
571.00
232.00
160.00
Accounts Payable
612.00
2,412.00
3,661.00
22,883.00
9,256.00
Income Tax Payable
130.00
-
859.00
-
-
Other Current Liabilities
2,945.00
22,417.00
9,749.00
14,790.00
12,615.00
Total Current Liabilities
3,876.00
25,021.00
14,840.00
37,905.00
22,031.00
Long-Term Debt
7,033.00
941.00
6,368.00
6,285.00
6,111.00
Other Liabilities
1,321.00
2,323.00
1,560.00
1,091.00
998.00
Total Liabilities
12,230.00
28,285.00
22,768.00
45,281.00
29,140.00
Common Equity (Total)
58,327.00
203,777.00
195,774.00
129,466.00
151,557.00
Total Shareholders' Equity
58,327.00
203,777.00
195,774.00
129,466.00
151,557.00
Total Equity
58,327.00
203,777.00
195,774.00
129,466.00
151,557.00
Liabilities & Shareholders' Equity
70,557.00
238,062.00
218,542.00
174,747.00
180,697.00
Non-Equity Reserves
-
6,000.00
-
-
-

About NewLink Genetics

View Profile
Address
2503 South Loop Drive
Ames Iowa 50010
United States
Employees -
Website http://www.newlinkgenetics.com
Updated 07/08/2019
NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications.